- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 18.08. | CANNAPHARMARX, INC. - 10-Q, Quarterly Report | 4 | SEC Filings | ||
| 17.08. | CANNAPHARMARX, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| CANNAPHARMARX Aktie jetzt für 0€ handeln | |||||
| 20.05. | CANNAPHARMARX, INC. - 10-Q, Quarterly Report | 2 | SEC Filings | ||
| 18.05. | CANNAPHARMARX, INC. - NT 10-Q, Notification of inability to timely file Form 10-Q or 10-QSB | 1 | SEC Filings | ||
| 31.03. | CANNAPHARMARX, INC. - 10-K, Annual Report | - | SEC Filings | ||
| 13.01. | CannaPharmaRX Provides Corporate Update and Outlines Growth Strategy for 2026 | 535 | ACCESS Newswire | CALGARY, AB / ACCESS Newswire / January 12, 2026 / CannaPharmaRX, Inc. (OTC PINK:CPMD), an emerging leader in global cannabis cultivation and export, is pleased to provide a corporate update outlining... ► Artikel lesen |
6 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| ETON PHARMACEUTICALS | 59,49 | 0,00 % | Biotech Stocks At 52-Week Highs - Eton Pharmaceuticals +44%, DexCom, Oruka Therapeutics, Concentra Group Holdings Parent, AtaiBeckley | INDIANAPOLIS (dpa-AFX) - The following biotech stocks reached 52-week highs on August 14, 2026, following positive quarterly reports or an announced upcoming acquisition. Eton Pharmaceuticals... ► Artikel lesen | |
| BAYER | 49,490 | +0,22 % | EQS-PVR: Bayer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung | EQS Stimmrechtsmitteilung: Bayer Aktiengesellschaft
Bayer AG: Veröffentlichung gemäß § 40 Abs. 1 WpHG mit dem Ziel der europaweiten Verbreitung
18.09.2026 / 10:04 CET/CEST
Veröffentlichung... ► Artikel lesen | |
| GENERATE BIOMEDICINES | 15,990 | 0,00 % | Generate Biomedicines auf dem Bernstein Healthcare Forum: Daten statt Modelle | ||
| KARDIGAN | 14,390 | 0,00 % | Citi's U.S. Consumer Cards Business To Buy Kard Financial For Undisclosed Terms | WASHINGTON (dpa-AFX) - Banking major Citigroup Inc. (C) announced late Thursday that its U.S. Consumer Cards business has agreed to acquire Kard Financial, a commerce media and rewards platform.... ► Artikel lesen | |
| AQUESTIVE THERAPEUTICS | 4,820 | 0,00 % | Aquestive Therapeutics, Inc.: Aquestive Therapeutics Announces Resubmission of New Drug Application to FDA for Anaphylm (dibutepinephrine) Sublingual Film | Resubmission supported by positive topline human factors and pharmacokinetic (PK) study results announced in August 2026FDA will determine the resubmission classification and establish the applicable... ► Artikel lesen | |
| MERCK KGAA | 135,30 | +1,01 % | Community-Rückblick: "Moderna wäre um min. 50% gestiegen, BioNTech bisher nicht mal 2%. That's it!" | © Foto: Julia Cebella - dpaNeue Onkologie-Daten sorgen bei BioNTech für Diskussionen: Warum reagiert die Aktie trotz guter Studienergebnisse kaum? Die wO User Diskutieren über Pipeline, Bewertung und... ► Artikel lesen | |
| LB PHARMACEUTICALS | 37,790 | -0,03 % | LB Pharmaceuticals auf TD Cowen Summit: Wirkstoffkandidat LB-102 zielt auf sicherere psychiatrische Behandlungen ab | ||
| JAGUAR HEALTH | 7,010 | -0,71 % | Morning Market Movers: Wheeler REIT, Professional Diversity Network, Jaguar Health, Greenland Mines See Big Swings | BEIJING (dpa-AFX) - At 6:50 a.m. ET on Wednesday, premarket trading is seeing notable activity in several stocks, with early price movements signaling potential opportunities before the opening... ► Artikel lesen | |
| KAZIA THERAPEUTICS | 9,690 | -0,92 % | Kazia Therapeutics Limited: Kazia Therapeutics Announces Sovargen Co. Doses First Patient in Phase 1b/2a Trial of Paxalisib for Rare Seizure Disorders | Clinical Milestone Expands Development of Paxalisib Beyond Oncology and Triggers $2 Million Payment to Kazia
SYDNEY, Sept. 22, 2026 /PRNewswire/ -- Kazia Therapeutics... ► Artikel lesen | |
| NOVO NORDISK | 33,790 | +0,33 % | Neuer Pharma-Player: Anthropic geht heimlich ins Labor - der nächste große KI-Coup? | © Foto: Andrej Sokolow - dpaAnthropic drängt in die Biowissenschaften und baut dafür ein eigenes Labor auf. Der KI-Konzern will die Medikamentenentwicklung massiv beschleunigen Enthaltene Werte: US1101221083... ► Artikel lesen | |
| OMNIAB | 4,800 | 0,00 % | Veraxa Biotech AG: VERAXA Biotech Announces Advancement of Novel Bispecific Antibody Drug Conjugate Program VXA-222 from Joint Discovery Collaboration with OmniAb | VXA-222 advances into next phase at VERAXAZURICH, SWITZERLAND, July 27, 2026 --
VERAXA Biotech AG (NASDAQ: VRXA; "VERAXA" or the "Company"), an emerging leader in designing novel cancer therapies... ► Artikel lesen | |
| JOURNEY MEDICAL | 6,330 | +0,16 % | Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights | Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter Emrosi revenues were $8.1 million for the second quarter of 2026 Strong revenue... ► Artikel lesen | |
| APNIMED | 21,590 | -0,18 % | Apnimed, Inc.: Apnimed Reports Second Quarter 2026 Financial Results and Provides Corporate Update | U.S. Food and Drug Administration ("FDA") Accepted the NDA for AD109, with a proposed proprietary name Oxnimbi- and assigned a PDUFA target action date of February 28,- 2027 If approved, Oxnimbi... ► Artikel lesen | |
| SANOFI | 71,81 | -2,01 % | Sanofi vertieft den F&E-Umbau - das steckt dahinter | ||
| TURN THERAPEUTICS | 13,420 | +1,21 % | Lucid Capital Markets initiates Turn Therapeutics stock with buy rating |
Das Unternehmen CANNAPHARMARX INC kann der Branche Pharma zugeordnet werden.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANNAPHARMARX INC finden Sie auf Wallstreet Online.